外周静脉给予23.4%氯化钠的安全性
该回顾性观察性队列研究在一家719张床位的学术医学中心(一级创伤中心)和一家247张床位的学术社区医院进行,纳入2015年3月29日至2023年10月21日期间经外周静脉接受至少一次30 mL 23.4%氯化钠团注的18岁以上患者,排除给药后24小时内死亡或出院者。主要终点为外周给予23.4%氯化钠的外渗,采用Naranjo药物不良反应概率量表评估,863次给药中发生56次(6.4%)。无组织坏死病例、无外科干预,仅1例使用透明质酸酶药物干预。有糖尿病史者发生23.4%氯化钠外渗事件的风险为无糖尿病史者的2.39倍(95%CI 1.41-4.05,p=0.001)。作者认为外周给予23.4%氯化钠外渗率低,发生可能或很可能外渗事件的患者无显著损伤,糖尿病可能是外渗的危险因素。
要点
- 863次外周静脉给予23.4%氯化钠中发生外渗56次(6.4%),评估采用Naranjo药物不良反应概率量表。
- 外渗后无组织坏死病例、无外科干预,仅1例使用透明质酸酶进行药物干预。
- 有糖尿病史者发生23.4%氯化钠外渗事件的风险为无糖尿病史者的2.39倍(95%CI 1.41-4.05,p=0.001)。
- 所有研究对象均经外周静脉接受至少一次30 mL的23.4%氯化钠团注。
- 给药后24小时内死亡或出院者被排除,作者结论为外周给药外渗率低且无显著损伤,糖尿病可能是外渗危险因素。
适用人群与场景
- 18岁以上、于2015年3月29日至2023年10月21日期间入住一家719张床位的学术医学中心(一级创伤中心)或一家247张床位的学术社区医院、经外周静脉接受23.4%氯化钠的患者。
- 排除给药后24小时内死亡或给药后不足24小时出院者。
- 所有研究对象均经外周静脉导管接受至少一次30 mL的23.4%氯化钠团注。
诊断标准与关键阈值
- 外渗判定采用Naranjo药物不良反应概率量表评估。
处置流程与药物剂量
- 经外周静脉导管给予23.4%氯化钠,每次至少30 mL团注(研究方案给药方式)。
- 外渗后仅1例使用透明质酸酶进行药物干预,无外科干预。
研究设计与关键结果
- 研究类型为回顾性观察性队列研究,纳入863次经外周静脉给予23.4%氯化钠的给药事件。
- 主要终点外渗发生56/863次(6.4%),采用Naranjo药物不良反应概率量表评估。
- 无组织坏死病例,无外科干预,1例使用透明质酸酶药物干预。
- 有糖尿病史者发生23.4%氯化钠外渗事件的风险为无糖尿病史者的2.39倍(95%CI 1.41-4.05,p=0.001)。
证据类型、等级与局限
- 证据类型:回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为外周给予23.4%氯化钠外渗率低(6.4%),发生可能或很可能外渗事件的患者无显著损伤。
- 作者认为糖尿病可能是外渗的危险因素,有糖尿病史者外渗风险为无糖尿病史者的2.39倍(95%CI 1.41-4.05,p=0.001)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: For patients with increased intracranial pressure, prompt initiation of hyperosmolar therapy with 23.4% sodium chloride may minimize permanent neurological damage and prevent cerebral herniation. Placement of a central venous catheter can delay time to osmotherapy and may negatively impact patient outcomes. The objective of this study was to examine the safety of 23.4% sodium chloride administered through a peripheral intravenous (IV) catheter.
METHODS: This was a retrospective observational cohort study conducted at a large academic health system. Patients were admitted to one 719-bed academic medical center and a level I trauma center or one 247-bed academic community hospital. Study participants were 18 years or older, admitted between March 29, 2015, and October 21, 2023, and received 23.4% sodium chloride through a peripheral IV. Patients who died within 24 h of 23.4% sodium chloride administration or were discharged less than 24 h after administration were excluded. All study participants received at least one 30 mL bolus of 23.4% sodium chloride administered through a peripheral IV catheter.
RESULTS: The primary outcome, defined as extravasation of peripherally administered 23.4% sodium chloride, was assessed using the Naranjo Adverse Drug Reaction Probability Scale and occurred in 56 of 863 administrations (6.4%). Secondary outcomes included incidence of tissue necrosis, interventions used to treat extravasations, and attributable risk factors for extravasation. There were no cases of tissue necrosis, no surgical interventions performed, and one case of medical intervention using hyaluronidase. Patients with a history of diabetes had a 2.39 times higher risk of experiencing a 23.4% sodium chloride extravasation event (95% CI 1.41-4.05, p = 0.001).
CONCLUSIONS: Peripheral administration of 23.4% sodium chloride was associated with a low rate of extravasation and no significant injury in patients who did experience a possible or probable extravasation event. Diabetes mellitus was a possible risk factor for extravasation.
参考来源
- Silva CR, Nagy J, Zullo AR, et al. Safety of Peripherally Administered 23.4% Sodium Chloride. Neurocrit Care. 2025. PMID: 40841787. doi:10.1007/s12028-025-02342-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。